All Articles

As part of Stony Brook University, a flagship university of the State University of New York system, the Stony Brook Cancer Center provides a full spectrum of services from primary to tertiary care across both inpatient and outpatient sites.

Please join us live or virtually this May 17-21 in Orlando, FL, for the AONN+ Midyear Conference—the only conference dedicated to oncology nurse and patient navigators!

This edition of Year in Review is focused on multiple myeloma (MM), a disease for which the treatment landscape has seen tremendous growth resulting in major favorable changes in patient outcomes. New treatments have been approved and novel classes of agents continue to be investigated, particularly in the relapsed/refractory multiple myeloma (RRMM) setting. We are providing this Year in Review series to disseminate the latest information on treatment advances in 2022 to clinicians in a timely and effective manner.

The addition of ASCT to triplet induction with lenalidomide, bortezomib, and dexamethasone (RVd) and lenalidomide maintenance resulted in significant PFS benefit versus RVd alone.

Final results from LYRA demonstrated robust responses with dara + CyBorD induction, which deepened with dara maintenance.

Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM.

Cohort B of CARTITUDE-2 evaluated the safety and efficacy of cilta-cel in high-risk patients who experienced early clinical relapse to determine its use in earlier lines of therapy.

A discrete-choice experiment and best-worst scaling survey identified the most and least important multiple myeloma treatment characteristics to patients and their caregivers.

Long-term outcomes from MAIA support the use of daratumumab plus lenalidomide and dexamethasone for ≥18 months in newly diagnosed, transplant ineligible MM patients.